Immunogenicity of Therapeutic Proteins: The Use of Animal Models
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Immunogenicity of therapeutic proteins lowers patient well-being and drastically increases therapeutic costs. Preventing immunogenicity is an important issue to consider when developing novel therapeutic proteins and applying them in the clinic. Animal models are increasingly used to study immunogenicity of therapeutic proteins. They are employed as predictive tools to assess different aspects of immunogenicity during drug development and have become vital in studying the mechanisms underlying immunogenicity of therapeutic proteins. However, the use of animal models needs critical evaluation. Because of species differences, predictive value of such models is limited, and mechanistic studies can be restricted. This review addresses the suitability of animal models for immunogenicity prediction and summarizes the insights in immunogenicity that they have given so far.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Arzneimittelforschung · doi:10.1055/s-00000175 · Cited by 1,134
Immunogenicity of therapeutic proteins: Clinical implications and future prospects
Schellekens, H. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80075-3 · Cited by 556
Self-citationImmunogenicity of protein therapeutics
De Groot, A. S., & Scott, D. W. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.07.011 · Cited by 545
Factors influencing the immunogenicity of therapeutic proteins
Schellekens, H. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh1092 · Cited by 332
Self-citationPrinciples, approaches, and challenges for predicting protein aggregation rates and shelf life
Weiss, W. F., Young, T. M., & Roberts, C. J. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21521 · Cited by 308
Braun, A., Kwee, L., Labow, M. A., & Alsenz, J. (1997) · Pharmaceutical Research · doi:10.1023/a:1012193326789 · Cited by 298
Koren, E., Zuckerman, L., & Mire-Sluis, A. (2002) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023378175 · Cited by 267
Vultaggio, A., Matucci, A., Nencini, F., Pratesi, S., Parronchi, P., Rossi, O., Romagnani, S., & Maggi, E. (2010) · Allergy · doi:10.1111/j.1398-9995.2009.02280.x · Cited by 238
Immunological mechanism underlying the immune response to recombinant human protein therapeutics
Sauerborn, M., Brinks, V., Jiskoot, W., & Schellekens, H. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.11.001 · Cited by 207
Self-citationHermeling, S., Schellekens, H., Maas, C., Gebbink, M. F. B. G., Crommelin, D. J. A., & Jiskoot, W. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20599 · Cited by 185
Self-citation
Research works printed but not linked: 2
- EMA. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. 2007. Ref Type: Conference Proceeding
- Center for Biologics Evaluation and Research. Meeting of the biological response modifiers advisory committee. July 15, Bethesda MD. Food and Drug Administration. 1999. Ref Type: Conference Proceeding
Cited by
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
Van Norman, G. A. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.008 · Cited by 732
“Safety concerns include cross reactivity, potentially exaggerated pharmacology, and slow recovery from toxicity, among others (15,24)—and immunogenic responses in animals do not predict immunogenicity in humans (15,25–27).”
BackgroundMicroneedle technologies for (trans)dermal drug and vaccine delivery
van der Maaden, K., Jiskoot, W., & Bouwstra, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.042 · Cited by 651
Self-citationImmunogenicity of therapeutic proteins: Influence of aggregation
Ratanji, K. D., Derrick, J. P., Dearman, R. J., & Kimber, I. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2013.821564 · Cited by 589
Szebeni, J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.038 · Cited by 457
Metadata
- Authors
- Brinks, V., Jiskoot, W., & Schellekens, H.
- Affiliations
- Utrecht University (NL)
- Leiden University (NL)
- Corresponding author
- Brinks, Vera
- Venue
- Pharmaceutical Research
- Published
- 2011-07-09
- Volume
- 28
- Issue
- 10
- Pages
- 2379-2385
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- PMC
- PMC3170476
- OpenAlex
- W2114029270
- Cited by
- 164
- References
- 40
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 6 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 9 · 2019: 16 · 2018: 11 · 2017: 8 · 2016: 10 · 2015: 17 · 2014: 17 · 2013: 19 · 2012: 18
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Pharmaceutical Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- immunogenicity, therapeutic proteins, animal models, species differences, drug development
- MeSH terms
- Animals, Biological Products, Drug Evaluation, Preclinical, Humans, Predictive Value of Tests, Proteins, Models, Animal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunogenicity of Therapeutic Proteins: The Use of Animal Models. https://app.cochat.ai/papers/10.1007/s11095-011-0523-5
- The paper
- Brinks, V., Jiskoot, W., & Schellekens, H. (2011). Immunogenicity of Therapeutic Proteins: The Use of Animal Models. Pharmaceutical Research. https://doi.org/10.1007/s11095-011-0523-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.